Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aurelius Health Group vs Shapely

Aurelius Health Group
Graded #311

Lower grade

vs+4.6000000000000085
Shapely
Graded #220

Higher grade

The verdict

Shapely takes it — 65.4/100 to 60.8/100.

Shapely grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Shapely is a GLP-1 telehealth platform founded by Dr.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAurelius Health Group +9
54
45
Dose & formulationShapely +1
52
53
Clinical oversightShapely +18
76
94
Labs & monitoringShapely +10
63
73
FulfillmentShapely +17
61
78
Contract termsAurelius Health Group +6
61
55
Aurelius Health Group · left barShapely · right bar

The numbers

MetricAurelius Health GroupShapely
WeighScore60.8/10065.4/100
GradeCC
Scorecard rank#311#220
SemaglutideNot disclosedNot disclosed
Tirzepatide$199/mo (microdose tier, compounded)Not disclosed
CoverageCoverage not published4 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Aurelius Health Group

Graded #311 · C

Strengths

  • Pricing fully published and bundled: $89 first month, then $199/mo all-in — more transparent than most compounded brands
  • LegitScript Certified
  • Care-inclusive model: consults, monthly monitoring, and secure messaging rather than Rx-only
  • Unusually candid about the limited evidence base for microdosing

Where it loses points

  • The advertised $89 is a first-month new-patient rate; every month after it is $199
  • This is a 1 mg microdose programme and nothing else — no labelled therapeutic dose is sold, so it is not an alternative to a full-dose prescription
  • No state count is published, only 'most US states', confirmed at intake
  • The site's own comparison table calls 2.4 mg/week the tirzepatide 'standard full dose'; 2.4 mg is the semaglutide maintenance dose, and tirzepatide is labelled 2.5-15 mg/week
  • Compounded tirzepatide is not an FDA-approved finished product
Shapely

Graded #220 · C

Strengths

  • Founded by Dr. Justin Zaghi, MD/MBA — Harvard-trained, board-certified in internal medicine and obesity medicine, with Medical Director Ana Lisa
  • Brand-name GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo) covered by major PPO and Medicare at copay
  • Compounded semaglutide from $99/month with free 2-day shipping, syringes, and supplies included via 503A/503B pharmacy
  • 1:1 registered dietitian (RDN) and monthly video provider visits included in every plan; unlimited chat and app support
  • Cellular smart scale provided to qualifying patients for ongoing weight tracking throughout the program

Where it loses points

  • Currently available only in California, Florida, New York, and Texas — 46 states unserved despite announced expansion
  • Telehealth subscription ($99/mo self-pay, $49 first-month promo) is charged separately from compounded medication cost
  • Labs not included — $75 flat rate for uninsured patients; baseline bloodwork may be required before prescribing
  • No LegitScript certification found on any public page
  • Compounding pharmacy partner not named publicly; 503A/503B status claimed but specific pharmacy undisclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard